Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Investigating central nervous system toxicity and safety of commonly used anti-human immunodeficiency virus drugs

EF 2024-25

Résumé
Dolutegravir (DTG), in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC), is the first-line antiretroviral therapy (ART) for HIV due to its efficacy and safety. Despite viral suppression, central nervous system (CNS) inflammation persists, contributing to neurocognitive disorders in people living with HIV. DTG has been shown to disrupt brain barriers, i.e., blood-brain barrier and blood-cerebrospinal fluid barrier, by inducing inflammation, a potential cause for neuropsychiatric adverse effects (NPAEs) observed clinically. Interestingly, nucleoside reverse transcriptase inhibitors (NRTIs) like TAF and FTC have shown anti-inflammatory properties independent of their antiviral activity. This study aims to investigate whether TAF+FTC can mitigate DTG-induced CNS inflammation at the blood-brain interfaces. We will assess TAF+FTC effects on DTG-induced inflammatory responses in primary mouse brain microvascular endothelial cells by treating them with DTG alone or in combination with TAF+FTC, measuring changes in inflammatory cytokines/chemokines using qPCR and ELISA. To assess anti-inflammatory mechanisms, inflammation will be triggered using the cytokine IL-6, followed by TAF+FTC treatment. In vivo, mice will receive TAF+FTC alone or with DTG, CNS inflammatory responses will be evaluated by analyzing choroid plexus tissues and brain capillaries. Understanding the potential anti-inflammatory effects of TAF+FTC against DTG-induced CNS inflammation is crucial for optimizing HIV treatment regimens. This work may uncover opportunities to repurpose NRTIs as dual therapy, suppressing viral replication and protecting the CNS.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530245
Name
QU QING RUI (Simon)
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating central nervous system toxicity and safety of commonly used anti-human immunodeficiency virus drugs
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antiretroviral Therapy (Art); Blood-Brain Barrier (Bbb) Disruption; Dolutegravir (Dtg); Emtricitabine (Ftc); Human Immunodeficiency Virus (Hiv); Integrase Strand Transfer Inhibitors (Insti); Neuroinflammation; Neuropsychiatric Adverse Effects (Npaes); Nucleoside Reverse Transcriptase Inhibitors (Nrtis); Tenofovir Alafenamide (Taf)
Abstract
Dolutegravir (DTG), in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC), is the first-line antiretroviral therapy (ART) for HIV due to its efficacy and safety. Despite viral suppression, central nervous system (CNS) inflammation persists, contributing to neurocognitive disorders in people living with HIV. DTG has been shown to disrupt brain barriers, i.e., blood-brain barrier and blood-cerebrospinal fluid barrier, by inducing inflammation, a potential cause for neuropsychiatric adverse effects (NPAEs) observed clinically. Interestingly, nucleoside reverse transcriptase inhibitors (NRTIs) like TAF and FTC have shown anti-inflammatory properties independent of their antiviral activity. This study aims to investigate whether TAF+FTC can mitigate DTG-induced CNS inflammation at the blood-brain interfaces. We will assess TAF+FTC effects on DTG-induced inflammatory responses in primary mouse brain microvascular endothelial cells by treating them with DTG alone or in combination with TAF+FTC, measuring changes in inflammatory cytokines/chemokines using qPCR and ELISA. To assess anti-inflammatory mechanisms, inflammation will be triggered using the cytokine IL-6, followed by TAF+FTC treatment. In vivo, mice will receive TAF+FTC alone or with DTG, CNS inflammatory responses will be evaluated by analyzing choroid plexus tissues and brain capillaries. Understanding the potential anti-inflammatory effects of TAF+FTC against DTG-induced CNS inflammation is crucial for optimizing HIV treatment regimens. This work may uncover opportunities to repurpose NRTIs as dual therapy, suppressing viral replication and protecting the CNS.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
QU, QING RUI (Simon)
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~